 We hypothesize that the combination of the thin-strut MULTI-LINK i.e. VISIONtm andor MINI-VISIONtm stent and pharmacologic therapy with the oral PPAR-gamma agonist rosiglitazone will significantly reduce restenosis after intracoronary stenting in type 2 diabetic patients. This approach would present a more effective and economical alternative to the use of drug-eluting stents to reduce stent restenosis. 